Target was Hit on BioCryst Pharma $BCRX at $11 for a 21.5 % Gain (Long Term Portfolio).
Target was Hit on BioCryst Pharma $BCRX at $11 for a 21.5 % Gain (Long Term Portfolio).
Target was Hit on BioCryst Pharma $BCRX at $11 for a 21.5 % Gain (Long Term Portfolio).